October 12, 2012 4:04 PM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Watson Pharmaceuticals(NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc. hasreceived approval from the U.S. Food and Drug Administration (FDA) on itsAbbreviated New Drug Application (ANDA) for Irbesartan Tablets USP, 75 mg, 150mg and 300 mg, the generic equivalent to Sanofi's Avapro^®. Watson intends tobegin shipping the product immediately. Avapro^® is indicated for the treatment of hypertension when used alone or incombination with other antihypertensive agents. It is also indicated for thetreatment of diabetic nephropathy with an elevated serum creatinine andproteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension.For the 12 months ending August 31, 2012, Avapro^® and its generic equivalentshad total U.S. sales of approximately $390 million according to IMS Healthdata.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.